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Abstract
Background: The use of bone marrow-derived human multipotent stromal cells (hMSC) in cell-based therapies has
dramatically increased in recent years, as researchers have exploited the ability of these cells to migrate to sites of tissue
injury, inflammation, and tumors. Our group established that hMSC respond to ‘‘danger’’ signals – by-products of damaged,
infected or inflamed tissues – via activation of Toll-like receptors (TLRs). However, little is known regarding downstream
signaling mediated by TLRs in hMSC.
Methodology/Principal Findings: We demonstrate that TLR3 stimulation activates a Janus kinase (JAK) 2/signal transducer
and activator of transcription (STAT) 1 pathway, and increases expression of suppressor of cytokine signaling (SOCS) 1 and
SOCS3 in hMSC. Our studies suggest that each of these SOCS plays a distinct role in negatively regulating TLR3 and JAK/
STAT signaling. TLR3-mediated interferon regulatory factor 1 (IRF1) expression was inhibited by SOCS3 overexpression in
hMSC while SOCS1 overexpression reduced STAT1 activation. Furthermore, our study is the first to demonstrate that when
TLR3 is activated in hMSC, expression of CXCR4 and CXCR7 is downregulated. SOCS3 overexpression inhibited
internalization of both CXCR4 and CXCR7 following TLR3 stimulation. In contrast, SOCS1 overexpression only inhibited
CXCR7 internalization.
Conclusion/Significance: These results demonstrate that SOCS1 and SOCS3 each play a functionally distinct role in
modulating TLR3, JAK/STAT, and CXCR4/CXCR7 signaling in hMSC and shed further light on the way hMSC respond to
danger signals.
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Introduction
Human MSC are excellent vehicles for cell-based therapeutics
because they are easily isolated and can be exponentially
expanded ex vivo. The use of hMSC in cell-based therapies has
dramatically increased in recent years, as researchers have also
exploited the ability of these cells to migrate to sites of tissue injury,
inflammation, and tumors. Numerous studies using hMSC
transplants have shown that these cells improve the outcome of
disease, especially autoimmune disorders [1,2,3,4,5,6,7], due to
their immunomodulatory properties [8,9,10]. In order to enhance
hMSC-based therapeutics, it is imperative to understand the
mechanisms by which hMSC are recruited to the target site, since
less than 0.1% of these cells engraft into the tissue [11,12,13,14].
Our group and others have demonstrated that MSC respond to
‘‘danger’’ signals – by-products of damaged, infected or inflamed
tissues – via activation of TLR signaling [15,16,17]. TLRs have
been shown to modulate proliferation, differentiation and migra-
tion of MSC, but these functional responses largely depend on
both the tissue and species from which the MSC were derived
[15,16,17,18,19]. Our group previously reported that activation of
TLR signaling produces a unique gene expression profile in
hMSC depending on the agonist with which they are treated. In
addition, stimulation of TLR3 led to unique responses from
hMSC including enhanced migratory ability. Exposure of hMSC
to TLR3 ligands may represent a distinct mechanism through
which these cells sense danger signals and preferentially migrate to
the target tissue in order to perform their reparative function.
Furthermore, studies from our group and others have also linked
TLR activation to the regulation of immunomodulatory factors in
hMSC, including indoleamine 2,3-dioxygenase and prostaglandin
E2 [18,19]. Taken together, emerging evidence indicates that
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migration, differentiation, and immunomodulation.
Although mounting evidence shows that TLRs contribute to
MSC function, little is known of what happens downstream of the
TLR signaling pathway, especially what factors may negatively
regulate TLR signaling and thus may also modulate MSC
function. Suppressor of cytokine signaling (SOCS) proteins are a
well established family of E3 ubiquitin ligases which can be
induced directly through TLR-mediated gene expression, or
indirectly by the expression of TLR-induced chemokines and
cytokines that activate the JAK/STAT pathway [20]. Several
studies have identified SOCS1 as a negative regulator of TLR
signaling by targeting TLR adaptors [21], intermediate signaling
components [22] and TLR-activated transcription factors [23] for
degradation or by inhibiting phosphorylation. The vast majority of
TLR-SOCS studies have centered on lipopolysaccharide-induced
TLR4 signaling and the role of SOCS1 as a negative regulator.
However, Hashimoto and colleagues found that polyinosinic:po-
lycytidylic acid (poly(I:C))-induced TLR3 signaling indirectly
induced SOCS1 expression in human keratinocytes, which
inhibited both TLR3-mediated STAT1 activation and chemokine
expression [24]. Conversely, Yang and colleagues found that
poly(I:C)-induced TLR3 activation resulted in the upregulation of
SOCS3 in murine dendritic cells, which inhibited TLR3 indirectly
by promoting degradation of tyrosine kinase 2 [25].
Furthermore, SOCS proteins have also been identified as
negative regulators of chemokine signaling by associating with the
receptor and inhibiting activation of signaling and function, such
as migration [26,27]. The Mellado group determined that SOCS3
upregulation in hematopoietic stem cells inhibited their retention
in the bone marrow, a function primarily regulated by CXCL12
expression [28], by inhibiting its receptor, CXCR4 [29].
Additionally, the Lider group examined how TLR activation
negatively regulates CXCR4 signaling through activation of
SOCS expression; TLR2 signaling inhibited CXCR4-mediated
T cell homing in a SOCS3-dependent mechanism [30].
Since the SOCS family is known to regulate various aspects of
immune cell function, including differentiation, proliferation and
migration [31], we hypothesized that SOCS may also play a role
in regulating TLR- and CXCR-mediated signaling within hMSC
[32,33,34,35,36,37].
In this study we determined that SOCS1 and SOCS3 each play
a unique role in negatively regulating TLR3-mediated signaling in
hMSC. The expression of SOCS1 inhibited JAK2/STAT1
signaling, while SOCS3 inhibited IRF1 signaling. We also
demonstrate for the first time that TLR3 signaling reduced cell
surface expression of both CXCR4 and CXCR7 by receptor
internalization and degradation in hMSC, which was disrupted
when SOCS were overexpressed. Collectively, these data suggest
that as negative regulators, SOCS proteins affect the way hMSC
function and thus may also play a pivotal role in hMSC immune
regulation with critical implications for hMSC-based therapies.
Materials and Methods
Human Multipotent Stromal Cells
Bone marrow-derived hMSC were used for all studies (Tulane
Center for Stem Cell Research and Regenerative Medicine, New
Orleans, LA; Lonza, Walkersville, MD). Human MSC are pre-
tested for their homogeneity and differential potential to chondro-,
osteo-, and adipogenic lineages by the suppliers. Our lab also
verified all hMSC were positive for CD90, CD105, CD106,
CD164, CD56, CD166, CD29, and CD44, and negative for
CD45, CD14, CD31, CD34, HLA DR and CD117 by flow
cytometry. Human MSC were cultured as previously described
[17]. All experiments were conducted on hMSC at a passage #5
with at least three different donors from the two differences sources
stated above.
Transfection and Vectors
Human MSC were transfected by electroporation using the
Invitrogen Neon system (Carlsbad, CA) according to the
manufacturer’s instructions using 2.5 mg vector per 1610
6 cells.
Human MSC were transfected with the SOCS overexpression
vectors, pORF5-hSOCS1 or pORF5-hSOCS3, or mock vector,
pORF5-MCS as indicated (Invivogen, San Diego, CA). Overex-
pression was confirmed 24 hours post transfection by Western blot
analysis. All transfected cells were allowed to recover overnight
before experimental treatments. Cell viability measured for the
hMSC following transfection was typically 90%. Transfection
efficiency with the optimized MSC protocol for Neon System was
typically 80% (Invitrogen).
TLR3 Ligand
To induce TLR3 activation, hMSC were treated with 10 mg/ml
of poly(I:C), a dsRNA analog (InvivoGen).




Human MSC were treated for 6 hours with poly(I:C), washed
twice, RNA was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA), and then treated using the TURBO DNA-free kit
(Ambion, Austin, TX). RNA was reverse transcribed and the
resulting cDNA was used in the JAK/STAT Signaling Pathway
RT
2 Profiler
TM PCR Array (SuperArray Bioscience, Frederick,
MD) according to the manufacturer’s instructions on an iCycler
iQ5 Real-Time PCR Detection System (Bio-Rad, Hercules, CA).
Raw data from both the untreated and treated groups were
analyzed using the GEarray Analyzer software (SuperArray Inc.,
Bethesda, MD).
Quantitative Real-Time PCR (qPCR)
Human MSC were treated for 6 hours with poly(I:C), RNA was
extracted using the RNeasy Mini Kit (Qiagen,), and then treated
using the TURBO DNA-free kit (Ambion). RNA was subsequently
reverse transcribed using the iScript
TM cDNA Synthesis kit
according to the manufacturer’s instructions (Bio-Rad). cDNA
was amplified in iQ SYBR Green Supermix (Bio-Rad) with the
following primers pairs: IRF1 - Forward 59-CTT CCA CCT CTC
ACC AAG AAC-39, Reverse 59-CCA TCA GAG AAG GTA
TCA GGG C-39; JAK2 - Forward 59-AAG AAA ACG ATC AAA
CCC CAC T-39 Reverse 59-TGC ATT GGC TGA ATT GCT
GAA-3’; SOCS1 - Forward 59-GCC TGC GGA TTC TAC TGG
G-3’, Reverse 59-TAA GGG CGA AAA AGC AGT TCC-3’; 18S
rRNA - Forward 59-GAG GGA GCC TGA GAA ACG G-39,
Reverse 59-GTC GGG AGT GGG TAA TTT GC-39 (IDT,
Coralville, IA), using the iCycler iQ5 Real-Time PCR Detection
System (Bio-Rad). Optimal primer efficiencies and cDNA
concentrations were determined before conducting real-time
PCR. As a reference gene, 18S rRNA specific primers were used.
The experimental samples and internal controls were run in
triplicate on the same plate. The qPCR reaction was carried out as
previously described [38]. Differences in gene expression were
determined by the Quantitative Comparative CT (threshold value)
method. qPCR was conducted using 5 separate RNA isolations
from 5 different hMSC donors.
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Human MSC were treated with poly(I:C) to induce TLR3
activation as indicated. Protein was isolated and concentration
measured as previously described [17]. Treatment was carried out
in triplicate per donor and then pooled together during protein
isolation. Approximately 20 mg of protein was then separated by
electrophoresis on a NuPage Novex 4–12% BIS-TRIS polyacryl-
amide gel (Invitrogen). Proteins were then transferred onto a
nitrocellulose membrane using the Invitrogen iBlot system.
Membranes were blocked for 1 hour with 5% non-fat dry milk
in Dulbecco’s phosphate buffered saline containing 0.2% Tween-
20 (DPBST). pJAK2
Y1007/1008, JAK2 (rabbit monoclonal antibod-





monoclonal antibodies; BD Biosciences, San Jose, CA), IRF-1,
SOCS1, SOCS3, CXCR4, or CXCR7 (rabbit polyclonal
antibodies; Abcam, Cambridge, MA) primary antibodies were
diluted in DPBST and incubated overnight at 4uC. After washing
3 times in DPBST, membranes were incubated for 1 hour in an
HRP-conjugated secondary antibody diluted (Amersham, Piscat-
away, NJ) in DPBST. Membranes were washed again, and
immunodetection of the protein was carried out using ECL
(Invitrogen) and imaged by the FUJI LAS-4000 Imager (Tokyo,
Japan). Restore Plus Stripping Buffer (Thermo Scientific, Wal-
tham, MA) was used to strip membrane, which were re-blocked
and incubated with a b-actin primary antibody as a normalizing
control (Sigma-Aldrich, St. Louis, MO). Each Western blot was
repeated a minimum of 3 times, each time with a different donor.
Band densitometry was determined using ImageJ software. After
subtracting overall background, experimental bands were first
normalized to the actin loading control band within each lane, and
then expressed as fold change from the untreated control band.
Data displayed are representative of the results obtained from 3
separate donors.
Flow Cytometry
Human MSC were treated with poly(I:C) for 0, 2, 4, or 6 hours,
harvested and analyzed by flow cytometry as previously described
using a CXCR4 or CXCR7 primary antibody and an Alexa-488-
conjugated secondary antibody (Invitrogen) [17]. Samples were
run on a BD FACSCalibur and analyzed using CellQuest Pro
software (BD Biosciences). Flow cytometry analysis was performed
using a minimum of 3 different hMSC donors and unstained cells
and isotype antibody controls served as negative controls.
Statistical significance was determined as follows: after subtracting
the mean fluorescence intensity (MFI) of the isotype control, the
MFI of each experimental histogram was expressed as fold change
from the untreated control.
Immunofluorescence Assay
Human MSC were plated onto tissue culture treated slides,
1.5610
4 cells/chamber and treated with poly(I:C) for 0, 2, 4 or 6
hours. Fluorescence immunocytochemistry was then performed as
previously described using a CXCR4 (Abcam, Invitrogen) and/or
CXCR7 (Abcam) primary antibody with an Alexa-488 conjugated
secondary antibody, and the nucleus was stained with 15 nM 4’,6-
diamidino-2-phenylindole (DAPI; Sigma) [17]. A minimum of 5
different human MSC donors from two sources was assayed in
duplicate. Unstained cells and cells stained with an Alexa-488
conjugated secondary antibody alone served as negative controls.
Slides were analyzed using a Zeiss Axio Plan II microscope and
SlideBook Version 5 Software. All photomicrographs were taken
with a 40X objective. Colocalization was determined by both the
Pearson’s and Manders’ coefficient using the ImageJ software
plugin, JACoP v2.0 [39].
Statistical Analysis
Data is presented as the mean 6 the standard error of the mean
(SEM). Data were analyzed by comparing the treated to untreated
groups by a two-tailed, unpaired t-test (GraphPad Prism Version
4). P-values below 0.05 were considered statistically significant.
Results
TLR3 Stimulation Activates a JAK2/STAT1 Pathway in
hMSC
TLR3 stimulation alters the expression of JAK/STAT-
related genes. In order to determine what components of the
JAK/STAT pathway may be affected by TLR3 stimulation, we
treated hMSC with the TLR3 agonist, poly(I:C), and performed a
human JAK/STAT Signaling Pathway RT
2 Profiler
TM PCR
Array. Among the 84 different JAK/STAT-related genes, we
found that JAK2 was elevated 9.85-fold, the transcription factor
IRF1 was upregulated 16-fold, and SOCS1 was upregulated 21.11-
fold; several other genes were also induced or inhibited at least 2-
fold following TLR3 stimulation (Table 1).
In order to verify these results, qPCR was performed on a select
number of genes that showed at least a two-fold increase or
decrease in mRNA expression after poly(I:C) treatment. TLR3
activation significantly induced IRF1 (16.0863.86), JAK2
(14.6864.67), and SOCS1 (31.74611.05) (Figure 1A). These
results follow the same trend as the JAK/STAT PCR array,
suggesting that TLR3 activation results in downstream signaling of
the JAK/STAT pathway.
JAK2 is upregulated and activated upon TLR3
stimulation. Given the induction of JAK2 mRNA following
TLR3 stimulation we next examined the effect of poly(I:C) on
JAK2 enzyme activation and expression. JAK2 phosphorylation
was evident 4 to 6 hours after poly(I:C) treatment of hMSC. In
addition, total expression levels of JAK2 steadily increased
beginning at the same time point (Figure 1B), further supporting
our qPCR results. Interestingly, TLR3 activation and subsequent
downstream signaling pathway activation was specific for JAK2,
since JAK1 and JAK3 were not phosphorylated following poly(I:C)
treatment (data not shown).
STAT1 is activated after 4 hours of TLR3
stimulation. After establishing that JAK2 is activated by
TLR3 stimulation we wanted to investigate which STATs were
subsequently activated to carry out the signaling pathway. STAT1
phosphorylation in hMSC treated with poly(I:C) showed a narrow
window of activation, between 2 and 6 hours of treatment. After 4
hours of stimulation, STAT1 activation peaked (Figure 1C).
While total STAT1 appears to have an inversely proportional
expression pattern as that of phosphorylated STAT1, this is only
an artifact due to the nature of the mouse monoclonal antibody
used, which preferentially binds to unphosphorylated STAT. By
contrast, Western blot analyses of phosphorylated STAT3 and
STAT5, using mouse monoclonal antibodies, showed that TLR3
stimulation was unable to activate either STAT; neither STAT3
nor STAT5 showed any changes in phosphorylation following
treatment (Figure S1). Collectively, these experiments suggest
that TLR3-mediated downstream signaling in hMSC is carried
out by JAK2 and STAT1.
SOCS Overexpression Disrupts STAT1 Activation
SOCS1 expression is altered following TLR3
activation. SOCS proteins are negative regulators of both
TLR3 and SOCS Affect CXCR4/7 Expression in hMSC
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TLR3-mediated signaling resulted in an upregulation of SOCS1
mRNA (Figure 1A), we then examined how TLR3 activation
affected SOCS1 protein expression. TLR3 stimulation did alter
SOCS1 expression, with an induction at 2 and 6 hours of
treatment, and reduced expression at 4 hours (Figure 2A). These
Western blot data suggest that during TLR3 activation, SOCS1
tightly regulates STAT1 phosphorylation and only allows for its
activation for a short period of time. SOCS1 expression was
inversely proportional to STAT1 phosphorylation, where reduced
SOCS1 expression at 4 hours of treatment allowed for peak
STAT1 phosphorylation. When SOCS1 expression then increased
at 6 hours of treatment, STAT1 activation was then diminished.
SOCS3 expression is also affected following TLR3
activation. Although our JAK/STAT Signaling Pathway RT
2
Profiler
TM PCR Array did not show any significant changes in
SOCS3 mRNA expression (data not shown), previous studies have
demonstrated that like SOCS1, SOCS3 also plays a role in
modulating both JAK/STAT and TLR signaling [20,22,40]. We
therefore decided to explore SOCS3 protein expression in hMSC
after TLR3 activation. At 6 hours of treatment, SOCS3
expression, like SOCS1, was also upregulated (Figure 2B).
SOCS1 overexpression inhibits STAT1 activation. We
then tested if either SOCS1 or SOCS3 was able to disrupt TLR3
signaling. As dsRNA is an agonist of the TLR3 pathway, we were
unable to perform knockdown studies using shRNA or siRNA to
inhibit SOCS1 or SOCS3, which would activate rather than
inhibit TLR signaling [17,19,41,42]. Given that confounding
potential, we chose to overexpress these SOCS and studied their
effects on the TLR3 pathway in this manner. hMSC were
transfected with either a SOCS1 or SOCS3 overexpression vector,
allowed to recover overnight, and then TLR3 stimulated. We
found that the untransfected, mock-transfected, and SOCS3-
overexpressing hMSC all showed robust STAT1 phosphorylation
after 4 hours of poly(I:C) treatment (Figure 2C). The SOCS1-
overexpressing hMSC, however, had diminished levels of STAT1
phosphorylation, demonstrating that only the overexpression of
SOCS1 was able to inhibit STAT1 activation. These results
support our previous Western blots of untransfected hMSC, where
the upregulation of SOCS1 at 6 hours of treatment correlated to a
decrease in STAT1 phosphorylation, thereby impeding the
signaling pathway.
SOCS3 overexpression inhibits IRF1
upregulation. Furthermore, when examining IRF1 expression
after TLR3 activation, we found that IRF1 was upregulated after 2
hours of treatment in untransfected, mock-transfected, and
SOCS1-overexpressing cells (Figure 2D). In contrast, SOCS3-
overexpressing hMSC showed no IRF1 upregulation after TLR3
activation.
Our results showed that SOCS1 reduced STAT1 activation
while SOCS3 inhibited IRF1 upregulation, which indicate that
SOCS1 and SOCS3 each play a distinct role in regulating TLR3
signaling in hMSC.
TLR3-mediated Internalization and Degradation of
CXCR4 and CXCR7
TLR3 activation leads to attenuated cell surface
expression of CXCR4. CXCR4 is a known mediator of
hMSC migration, and a recent study found that TLR4 signaling
resulted in the downregulation of CXCR4 expression in
monocytes and neutrophils [34,43,44]. Thus, we were interested
to learn if TLR3 signaling had a similar effect on CXCR4
expression in hMSC. Using flow cytometric analysis on non-
permeabilized hMSC, we determined that surface expression of
CXCR4 decreased starting at 2 hours and continued through 6
hours of treatment (Figure 3A). Statistical analysis of the fold
change in mean fluorescence intensity (MFI) verified that surface
expression of CXCR4 on hMSC was significantly decreased at 6
hours of treatment (black) when compared to untreated hMSC
(red; p,0.01). Furthermore, Western blot analyses also indicated
that total CXCR4 expression steadily decreased, suggesting this
receptor is being internalized and subsequently degraded
Table 1. TLR3 stimulation alters the expression of JAK/STAT-related genes.
Gene Fold Change Gene Fold Change
Alpha-2-macroglobulin 2.30 V-myc myelocytomatosis viral oncogene homolog 22.30
Coagulation factor II (thrombin) receptor 23.25 Nuclear factor of kappa 1 (p105) 2.83
Colony stimulating factor 2 receptor, beta 22.30 Nitric oxide synthase 2A (inducible, hepatocytes) 8.00
C-X-C chemokine ligand 9 3821.70 2’,5’-oligoadenylate synthetase 1 111.43
Epidermal growth factor receptor 2.14 Platelet-derived growth factor receptor, alpha polypeptide 22.30
Erythropoietin receptor 22.46 STAT2 23.25
Fas (Tumor necrosis factor receptor superfamily, member 6) 2.64 SH2B adaptor protein 1 22.46
Fc fragment of immunoglobulin G, high affinity Ia,
receptor (CD64)
2.83 Signal transducing adaptor molecule 1 22.30
Guanylate binding protein 1, interferon-inducible, 67kDa 36.76 SOCS1 21.11
IRF1 16.00 STAT2 3.48
Interferon-stimulated transcription factor (ISG) 3, gamma 2.14 STAT4 2.64
Interleukin 2 receptor, gamma 6.50 STAT5A 4.59
ISG15 ubiquitin-like modifier 51.98 Upstream transcription factor 1 2.83
JAK2 9.85 YY1 transcription factor 2.64
Matrix metallopeptidase 3 13.00
RNA was isolated from hMSC treated for 6 hours with poly(I:C) and analyzed for 84 genes relating to JAK/STAT signaling using an RT
2 PCR array. Only genes with a
greater than 2-fold increase or decrease in expression are displayed.
doi:10.1371/journal.pone.0039592.t001
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activation as TLR3 stimulation was unable to promote any
phosphorylation on serine 339 of CXCR4 (unpublished data).
Therefore, this effect may likely be a TLR-mediated mechanism.
TLR3 activation also leads to CXCR7 internalization
from the cell surface. Current reports have indicated that
CXCR7, an atypical receptor also found to bind CXCL12, may
modulate CXCR4 function by heterodimerizing with CXCR4 or
by sequestering CXCL12 [45,46,47]. To date, only two studies
have reported that hMSC express CXCR7, yet its function
remains unknown [48,49]. Therefore, we examined whether TLR
signaling could similarly affect CXCR7 expression in hMSC as it
does with CXCR4. CXCR7 was expressed on the cell surface of
untreated, non-permeabilized hMSC, which substantially dimin-
ished following TLR3 activation (Figure 3C). Similar to CXCR4,
CXCR7 surface expression was also significantly decreased after 6
hours of treatment (aqua) when compared to untreated hMSC
(green; p,0.05). In addition, Western blot analyses also showed a
slight decrease in total CXCR7 expression after 6 hours of
treatment, indicating that CXCR7 is downregulated from the cell
surface following stimulation, but is not necessarily degraded
(Figure 3D).
CXCR4 and CXCR7 are Internalized Following TLR3
Activation
As our flow cytometric analyses suggested that TLR3 activation
results in decreased CXCR4 and CXCR7 surface expression, we
then observed the cellular distribution of these chemokine
receptors in hMSC. Immunofluorescence colocalization analyses
indicated that CXCR4 did colocalize with CXCR7 in hMSC with
a Pearson’s coefficient of 0.885; a value of 1 indicates total
colocalization. The Manders’ coefficients were 0.656 for CXCR4
overlapping CXCR7 (M1), and 0.83 for CXCR7 overlapping
CXCR4 (M2). As a Manders’ value of 0 indicates no colocaliza-
tion and 1 indicates total colocalization, these data suggest that
while only some of CXCR4 colocalizes with CXCR7, most of
CXCR7 colocalizes with CXCR4 (Figure S2F). Furthermore,
immunofluorescence staining of untreated hMSC exhibited a
diffuse expression of CXCR4 and CXCR7 throughout the
cytoplasm (Figure 4A, D, Figure S2A-E). However, beginning
at 4 hours of treatment, both CXCR4 (Figure 4 B, C, arrows/
insets) and CXCR7 (Figure 4 E, F, arrow) began to show a
punctate expression pattern, an indicator of receptor internaliza-
tion, which persisted through 6 hours of treatment.
Figure 1. TLR3 stimulation activates a JAK2/STAT1 pathway in hMSC. (A) Human MSC gene induction, following 6 hours of poly(I:C)
treatment, was analyzed by qPCR using 5 separate donors. Data are presented as mean 6 SEM. Significance was determined by comparing the
poly(I:C) treated samples to the untreated control. *p,0.05. (B-C) JAK2/STAT1 phosphorylation was analyzed by Western blot following TLR3
stimulation for 0–6 hours. Of note, the monoclonal STAT1 antibody preferentially binds total STAT1, which is why total STAT1 expression appears
inversely proportional to phosphorylated STAT1. Densitometry was determined by subtracting overall background, then each experimental band was
normalized to the actin loading control band within its lane, and fold change was calculated based upon the untreated control band. Density values
below each band are representative of results from 3 separate donors.
doi:10.1371/journal.pone.0039592.g001
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SOCS proteins have been demonstrated to inhibit CXCR4
signaling in immune cells [27]. To determine whether SOCS
proteins play a role in TLR3-mediated CXCR4 internalization,
we examined CXCR4 cellular distribution in hMSC overexpress-
ing SOCS. Mock-transfected and SOCS1-overexpressing hMSC
showed a CXCR4 expression pattern similar to that of
untransfected cells treated with poly(I:C) (Figure 5A-F). However,
hMSC overexpressing SOCS3 exhibited a decrease in punctate
CXCR4 staining (Figure 5H-I).
Flow cytometry analysis of surface CXCR4 expression on
SOCS-overexpressing hMSC further supports these findings.
Mock-transfected and SOCS1-overexpressing, non-permeabilized
hMSC treated with poly(I:C) had reduced expression of CXCR4
Figure 2. SOCS overexpression disrupts STAT1 activation. (A-B) SOCS1 and SOCS3 expression following TLR3 activation in hMSC by Western
blot analysis. (C) STAT1 activation in untransfected, mock-transfected, SOCS1- or SOCS3-overexpressing hMSC after 4 hours of poly(I:C) treatment. (D)
IRF1 expression in untransfected, mock-transfected, SOCS1- or SOCS3-overexpressing hMSC after 2 hours of poly(I:C) treatment. Density values below
each band are representative of results from 3 separate donors.
doi:10.1371/journal.pone.0039592.g002
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(Figure S3A). SOCS3-overexpressing hMSC, in contrast, did not
follow this trend; surface expression of CXCR4 only minimally
decreased following TLR3 activation.
These finding indicate that SOCS1 impedes TLR3-mediated
changes in CXCR4 expression.
SOCS1 and SOCS3 both Modulate the Subcellular
Location of CXCR7 in hMSC
Subsequently, we also wanted to determine how SOCS might
be affecting TLR3-mediated internalization of CXCR7 in hMSC.
Mock-transfected hMSC showed a similar punctate staining of
CXCR7 as that of untransfected hMSC following TLR3
activation (Figure 6A-C). In contrast, both SOCS1- and
SOCS3-overexpressing hMSC showed only a diffuse cytoplasmic
expression of CXCR7 following TLR3 stimulation (Figure 6D-I).
We also examined surface expression of CXCR7 in hMSC
overexpressing SOCS following TLR3 stimulation by flow
cytometry. In mock-transfected hMSC, CXCR7 expression
diminished from the cell surface while hMSC overexpressing
either SOCS1 or SOCS3 showed only a slight downregulation
after treatment, which confirms our immunofluorescence results
(Figure S3B). Therefore, these findings demonstrate that SOCS1
and SOCS3 are both able to disrupt TLR3-mediated CXCR7
internalization.
Discussion
This study was prompted by the lack of publications charac-
terizing the role of SOCS proteins in hMSC. The SOCS family of
proteins are well known negative regulators of the JAK/STAT
signaling pathways, and therefore serve to mediate both cytokine
and chemokine signaling in leukocytes and other non-immune
cells [31,50]. Previous studies have also identified a role for SOCS
proteins, mainly SOCS1 and SOCS3, as negative regulators of
TLR signaling [21,22,23,24,25,30,51], and reports from our
group and others have determined that TLRs are expressed and
functional in MSC [15,16,17,18,19]. While research is currently
underway investigating the role of TLRs in MSC biological
processes, including proliferation, differentiation, migration, and
immunomodulation [15,16,17,18,19], there were no known
studies exploring SOCS and MSC function.
This study established that in TLR3-stimulated hMSC, the
transcription factor, IRF1 was upregulated, and a JAK2/STAT1
downstream pathway was indirectly activated following an
Figure 3. TLR3-mediated internalization and degradation of CXCR4 and CXCR7. (A, C) TLR3-stimulated, non-permeabilized hMSC were
stained for cell-surface expression of CXCR4, CXCR7 or isotype control and analyzed by flow cytometry. Statistical significance was determined by
comparing the experimental mean fold change in MFI to the untreated control (black, p,0.05; aqua, p,0.01). (B, D) Western blot analysis of total
CXCR4 and CXCR7 expression following poly(I:C) treatment. Density values below each band are representative of results from 3 separate donors.
doi:10.1371/journal.pone.0039592.g003
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previously described [17,19]. Furthermore, both SOCS1 and
SOCS3 expression was upregulated after TLR3 signaling. Our
subsequent overexpression studies identified that SOCS1 and
SOCS3 each play a distinct role in negatively regulating TLR3
and JAK/STAT signaling pathways, where SOCS1 specifically
inhibited STAT1 activation, while SOCS3 inhibited IRF1
upregulation. Furthermore, these results collectively demonstrate
that SOCS1 and SOCS3 play a distinct role in modulating TLR3
and JAK/STAT signaling in hMSC, and have been incorporated
into a proposed signaling model (Figure 7).
Figure 4. CXCR4 and CXCR7 are internalized following TLR3 activation. Human MSC were plated on chamber slides and treated for 0, 4, or 6
hours with poly(I:C) and then stained with an Alexa-488 conjugated secondary only control, Alexa-488 labeled a-CXCR4 (A-C) or a-CXCR7 (D-F) and
DAPI. 40X. Scale bar represents 10 mm. Photomicrographs are representative of results from 5 separate donors.
doi:10.1371/journal.pone.0039592.g004
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39592In addition to these findings, we also identified a unique
chemokine receptor response in TLR3-stimulated hMSC. We
found that in TLR3-activated hMSC, CXCR4 expression was
internalized and degraded. Furthermore, we also determined
that TLR3 stimulation induced the internalization of CXCR7.
We propose that the removal of CXCR4 and CXCR7 by
internalization and/or degradation following TLR3 activation
may serve as one mechanism to prevent signaling of these
Figure 5. SOCS3 modulates the subcellular location of CXCR4 in hMSC. Mock-transfected (A-C), SOC1-overexpressing (D-F) or SOCS3-
overexpressing (G-I) hMSC were plated onto chamber slides and treated for 0, 4, or 6 hours with poly(I:C) and then stained with an Alexa-488
conjugated secondary only control or Alexa-488 labeled a-CXCR4 and DAPI. 40X. Scale bar represents 10 mm. Photomicrographs are representative of
results from 3 separate donors.
doi:10.1371/journal.pone.0039592.g005
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ligand. In support of this mechanism, we have previously shown
that migration assays using hMSC primed with TLR ligands
show an enhanced migratory ability towards a serum chemoat-
tractant, but only when pretreated for one hour [19]. In
contrast, we found that hMSC that were TLR3-primed for 24
hours showed a severely decreased migratory capacity towards a
serum chemoattractant. Since CXCR4 is a well-known mediator
Figure 6. SOCS1 and SOCS3 both modulate the subcellular location of CXCR7 in hMSC. Mock-transfected (A-C), SOC1-overexpressing (D-
F) or SOCS3-overexpressing (G-I) hMSC were plated onto chamber slides and treated for 0, 4, or 6 hours with poly(I:C) and then stained with an Alexa-
488 conjugated secondary only control or Alexa-488 labeled a-CXCR7 and DAPI. 40X. Scale bar represents 10 mm. Photomicrographs are
representative of results from 3 separate donors.
doi:10.1371/journal.pone.0039592.g006
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CXCL12, we might speculate that one reason we see a
decreased migration capacity towards a serum chemoattractant
following 24 hour TLR3 priming, is because this priming causes
the downregulation of CXCR4 from the hMSC cell surface
[34,44].
On a broader scale, by inhibiting CXCR4 signaling through
internalization, TLR-activated hMSC may no longer be retained
in the bone marrow by the presence of CXCL12, and may migrate
out of the bone marrow to sites of stress which secrete factors, or
danger signals, recognized by TLRs. Additionally, TLR signaling
may permit hMSC to efficiently migrate to a site of stress, by
temporarily depleting these receptors from the cell, thus inhibiting
retention in the bone marrow while also preventing its migration
toward other chemoattractants. Once they have reached their
targeted site, hMSC may then fulfill their immunomodulatory and
reparative functions.
Previous reports indicate that SOCS proteins also negatively
regulate chemokine signaling by docking to a target receptor, thus
inhibiting both signaling and cell function, such as migration
[26,27]. Our study found that TLR3-mediated internalization of
CXCR4 and CXCR7 was inhibited in hMSC overexpressing
SOCS. Flow cytometry and immunofluorescentce studies indicate
SOCS3 overexpression inhibited receptor internalization of
CXCR4 while both SOCS1 and SOCS3 overexpression prevent-
ed CXCR7 receptor internalization. These results suggest that
SOCS1 and SOCS3 may be modulating the TLR3-mediated
mechanism of CXCR4 and CXCR7 downregulation, and not
necessarily directly inhibiting the receptors themselves. If SOCS
were inhibiting these chemokine receptors, we would expect to see
a punctate staining pattern of these receptors in untreated, SOCS-
overexpressing hMSC.
Lastly, the signaling scheme we identified here downstream
from short-term stimulation of TLR3 to IFNR JAK/STAT
RSOCS 1/3R CXCR4/7 that drives the migration of the
hMSC appears to be even more complex than initially
anticipated. Indeed, we were not able to demonstrate a direct
effect on hMSC migration after specific inhibition of any one of
the downstream molecules by transwell, wound, or Boyden
assays. This implies that rather than linear signaling pathways
there must be various redundant pathways involved that
mediate hMSC migration. Further investigations are necessary
of the TLR-mediated down-regulation of CXCR4, CXCR7 and
potentially other chemokine receptors in hMSC after TLR
stimulation. This information is essential to improving hMSC-
based therapy that enhances the mobilization of the MSCs to
the targeted sites where they will be able to exert their
established immunomodulatory and reparative functions.
Supporting Information
Figure S1 TLR3 signaling activates neither STAT3 nor
STAT5. Phosphorylation levels of STAT3 (A) and STAT5 (B) in
hMSC following TLR3 activation was determined by Western
blot analysis. Densitometry was determined by subtracting overall
background, then each experimental band was normalized to the
actin loading control band within its lane, and fold change was
calculated based upon the untreated control band. Density values
below each band are representative of results from 3 separate
donors.
(TIF)
Figure 7. SOCS1 and SOCS3 inhibit TLR3 signaling in hMSC. TLR3 signaling induces cytokine expression and mediates the internalization of
both CXCR4 and CXCR7, as well as the degradation of CXCR4. A JAK2/STAT1 pathway is also activated, and subsequent upregulation of SOCS1 and
SOCS3 inhibits TLR3-mediated signaling by targeting different branches of the signaling pathways. SOCS1 inhibits STAT1 phosphorylation and CXCR7
internalization, while SOCS3 inhibits IRF1 upregulation and the internalization of both CXCR4 and CXCR7.
doi:10.1371/journal.pone.0039592.g007
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PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39592Figure S2 CXCR4 and CXCR7 are colocalized in hMSC.
Human MSC were plated onto chamber slides and stained with an
Alexa-568 and Alexa-488 conjugated secondary only control or an
Alexa-568 labeled a-CXCR4 (red) and Alexa-488 labeled a-
CXCR7 (green) and DAPI (blue). 40X. Scale bar represents
10 mm. Photomicrographs are representative of results from 3
separate donors. Both Manders’ and Pearson’s coefficients were
used to determine colocalization.
(TIF)
Figure S3 SOCS inhibits TLR3-mediated internaliza-
tion of CXCR4 and CXCR7. Human MSC that were mock-
transfected, or overexpressing either SOCS1 or SOCS3 were
stained for cell-surface expression of CXCR4 (A), CXCR7 (B) or
isotype control following TLR3 stimulation and analyzed by flow
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